Community/Retail

The FDA issued a drug safety communication regarding rare but severe pruritus associated with discontinuation of long-term use of cetirizine or levocetirizine.

Insulin costs soar despite a century of use—see how PBMs, rebates, and new policies shape access, and what pharmacists can do.

Sarah Nelson, PharmD, highlights how pharmacists are uniquely positioned to prevent heart disease by identifying cardiovascular risk early, improving medication adherence, and addressing lifestyle and social factors.

The FDA accepts Moderna’s mRNA flu vaccine filing, targeting adults 50 years and older, with an accelerated path for older adults and a 2026 decision deadline.

TrumpRx offers select branded drugs at cash prices outside insurance, requiring pharmacists to guide patients on cost comparisons, coverage limitations, and safe medication management, according to Ronna Hauser, PharmD.

Reevaluating menopause hormone therapy myths, risks, timing, and access.

Anne Cassity details the National Community Pharmacists Association's (NCPA's) next pharmacy benefit manager (PBM) reform priorities, focusing on fair pharmacy reimbursement and congressional scrutiny of health care consolidation and vertical integration.

Trusted pharmacist guidance, motivational interviewing, and evidence-based resources help parents make informed pediatric immunization decisions.

FDA approves difamilast (Adquey), a topical PDE4 inhibitor, expanding nonsteroidal options for mild to moderate atopic dermatitis in dermatology patients 2 years and older.

Serotonin transporter occupancy explains sertraline withdrawal symptoms and helps distinguish relapse.

Derek Webb and Dennis Williams outline practical, patient-centered strategies pharmacists can use to personalize OTC allergy recommendations, explain nondrowsy antihistamines clearly, and deliver efficient counseling in busy community settings.

This century has seen a dramatic shortage of pharmacists, then a dramatic pullback, and now a selective shortage. Will artificial intelligence tip the scale? If so, in which direction(s) and which settings of care?

Pitolisant is now the first and only FDA-approved nonscheduled treatment for cataplexy in pediatric and adult patients with narcolepsy.

Craig Beavers, PharmD, explores new phase 3 evidence on factor XIa inhibitors for secondary stroke prevention, highlighting OCEANIC-STROKE results, safety, and patient selection.

Joseph Saseen, PharmD, explains how population health strategies and team-based care create new opportunities for pharmacists to identify lipid treatment gaps and lead evidence-based ASCVD prevention.

Anne Cassity explains how Medicare Part D’s move to flat PBM service fees in 2028 may reduce incentives for high-cost formulary placement and support more cost-conscious medication decisions.

With user expectations changing and the need to support patients throughout their entire treatment journey, growing technology-enabled communication allows pharmacists to build stronger relationships and go beyond prescription fill.

Universal aspirin at the first prenatal visit lowers severe preeclampsia rates in high-risk pregnancies, delaying onset without raising hemorrhage or placental abruption risk.

ALZ-801, an oral anti–amyloid oligomer therapy, shows cognitive, functional, and brain-volume benefits in the mild cognitive impairment (MCI) stage of Alzheimer disease, with supportive biomarkers and no edema risk.

Allison Hill, PharmD, RPh, emphasizes that it is not too late for flu vaccination and highlights how pharmacists can address vaccine fatigue.

Niels Lund, expert investigator, reveals how early type 2 diabetes care slashes greenhouse gas emissions, boosts life years, and curbs costly complications.

Joseph Saseen, PharmD, highlights how pharmacists can close treatment gaps in dyslipidemia by initiating appropriate statin intensity early, using combination therapy when needed, and proactively assessing adherence.

Incretin-based therapies were associated with a lower risk of dementia compared with sulfonylureas in older adults with type 2 diabetes, highlighting potential cognitive benefits relevant to long-term diabetes management.

Anne Cassity of the NCPA outlines the historic passage of federal pharmacy benefit manager (PBM) reform and explains how new Medicare Part D contracting standards could reshape reimbursement and oversight for community pharmacies.

WADA tracks GLP-1s like Ozempic, Wegovy, and Zepbound at the Olympics as pharmacists weigh muscle-loss risks and sports pharmacy guidance.

Derek Webb and Dennis Williams discuss key global learnings from the FIP World Congress of Pharmacy, highlighting how pharmacists worldwide are leading proactive OTC allergy care and what practical strategies US community pharmacies can adopt.

Patients need evidence that reflects real benefit.

The label change removes boxed warnings of cardiovascular disease, breast cancer, and probable dementia from certain hormone replacement therapy products.